© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Merck's 21-Valent Adult-Specific Pneumococcal Vaccine Accrues New Phase 3 and Real World Data
March 19, 2024
The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.
Blood-Based DNA Test Shows Sensitivity of 83% for Colorectal Cancer
March 15, 2024
Findings from the ECLIPSE clinical trial showed the blood-based cancer screening test detects 83% of people with CRC, with a specificity of 90%.
Optinose Xhance approved by FDA as first medical therapy for CRS
March 15, 2024
Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.
Madrigal's Resmetirom Wins Historic FDA Approval for Noncirrhotic NASH
March 14, 2024
Resmetirom is the first-ever drug to be approved anywhere for management of the progressive liver disease.
AstraZeneca Launches Phase 3 THARROS Trial of Breztri to Reduce Cardiopulmonary Events in COPD
March 14, 2024
THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.
KDIGO Releases 2024 Clinical Practice Guideline for Evaluation and Management of CKD
March 14, 2024
The KDIGO 2024 CKD Practice Guideline is the first update since the 2012 iteration and so is based on the newest research on treatment and technology available.
Antisense Molecule against MASH from Ionis Meets Primary Endpoint in Phase 2 Trial
March 13, 2024
Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.
Pegazofermin Enters Phase 3 ENLIGHTEN Clinical Trial Program for MASH
March 13, 2024
The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.
Risk of Stroke Mitigated by Even Low Levels of Physical Activity
March 12, 2024
Even activity levels considered "insufficient" by guideline standards were found protective against stroke in this new systematic review and meta-analysis.
Tapinarof Cream 1.0% Effective for Atopic Dermatitis in Persons with Skin of Color: ADORING Phase 3 Program
March 11, 2024
Study participants self-identified as Black, White, or Asian and significant proportions reached improvement of ≥75% in EASI in both in ADORING 1 and ADORING-2.